Single Injection Adductor Canal Block Versus Continuous Adductor Canal Infusion for Total Knee Arthroplasty

Conditions:   Total Knee Arthroplasty;   Pain, Postoperative;   Adductor Canal Block
Interventions:   Procedure: Multimodal Peripheral Nerve Block Injection;   Procedure: Single Shot Adductor Canal Block
Sponsor:   Wake Forest School of Medicine
Not yet recruiting – verified December 2016

View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days

Leukotriene-Receptor Antagonists Versus Placebo in the Treatment of Asthma in Adults and Adolescents: A Systematic Review and Meta-Analysis.

Related Articles

Leukotriene-Receptor Antagonists Versus Placebo in the Treatment of Asthma in Adults and Adolescents: A Systematic Review and Meta-Analysis.

Ann Intern Med. 2015 Sep 22;

Authors: Miligkos M, Bannuru RR, Alkofide H, Kher SR, Schmid CH, Balk EM

Abstract
Background: Leukotriene-receptor antagonists (LTRAs) are recommended as an alternative treatment in patients with mild asthma, but their effect compared with placebo is unclear.
Purpose: To determine the benefits and harms of LTRAs as monotherapy or in combination with inhaled corticosteroids compared with placebo in adults and adolescents with asthma.
Data Sources: MEDLINE and the Cochrane Central Register of Controlled Trials from inception through June 2015.
Study Selection: Peer-reviewed, English-language, randomized, controlled trials in patients with asthma that reported the effect of LTRAs versus placebo on measures of asthma control.
Data Extraction: Three researchers extracted data on study population, interventions, outcome measures, and adverse events. One researcher assessed risk of bias.
Data Synthesis: Of the 2008 abstracts that were screened, 50 trials met eligibility criteria. Random-effects meta-analyses of 6 trials of LTRA monotherapy showed that LTRAs reduced the risk for an exacerbation (summary risk ratio [RR], 0.60 [95% CI, 0.44 to 0.81]). In 4 trials of LTRAs as add-on therapy to inhaled corticosteroids, the summary RR for exacerbation was 0.80 (CI, 0.60 to 1.07). Leukotriene-receptor antagonists either as monotherapy or add-on therapy to inhaled corticosteroids increased FEV1, whereas FEV1 percentage of predicted values was only improved in trials of LTRA monotherapy. Adverse event rates were similar in the intervention and comparator groups.
Limitation: Variation in definitions and reporting of outcomes, high risk of bias in some studies, heterogeneity of findings, possible selective outcome reporting bias, and inability to assess the effect of asthma severity on summary estimates.
Conclusion: Leukotriene-receptor antagonists as monotherapy improved asthma control compared with placebo, but which patients are most likely to respond to treatment with LTRAs remains unclear.
Primary Funding Source: National Institutes of Health.

PMID: 26390230 [PubMed – as supplied by publisher]

View full post on pubmed: asthma

Two Doses of the Intravenous Magnesium Sulfate Versus the Standard Single Dose ,With/ Without the Nebulized Budesonide For the Management of the Severe Asthma Exacerbation in the Emergency Room; A Randomized Controlled Trial.

Condition:   Bronchial Asthma
Interventions:   Drug: Intravenous magnesium sulfate;   Drug: Inhaled budesonide;   Drug: normal saline
Sponsor:   Hamad Medical Corporation
Recruiting – verified May 2015

View full post on ClinicalTrials.gov: asthma | received in the last 14 days